Protagonist Therapeutics, Inc. (PTGX) - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Protagonist Therapeutics, Inc. on March 23, 2022, covering the earliest event date of March 17, 2022. The Company is a Delaware corporation with its principal executive offices in Newark, California, and its common stock trades on The Nasdaq Stock Market LLC under the symbol "PTGX".
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance changes and does not contain financial performance data.
Material Changes
The primary material change reported is the departure of a senior executive:
- Resignation: Don Kalkofen, Chief Financial Officer (CFO), submitted his resignation effective April 1, 2022.
- Role Transition: Upon resignation, Mr. Kalkofen will cease to serve as the Company's principal financial and accounting officer.
- Succession: The Company has initiated a search for a replacement for Mr. Kalkofen.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on business outlook, or specific risk factors beyond the operational impact of the CFO departure. No unusual items or contingencies were disclosed in this report.
Key Facts for Investor Verification
- Confirm the timeline for the appointment of a new Chief Financial Officer.
- Verify if an interim CFO has been designated to serve between April 1, 2022, and the appointment of a permanent replacement.
- Review subsequent filings for any changes to the Company's financial reporting or internal controls resulting from this leadership transition.